Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4418.00
ASTM's Cash to Debt is ranked higher than
76% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ASTM: 4418.00 )
ASTM' s 10-Year Cash to Debt Range
Min: 9.5   Max: No Debt
Current: 4418

F-Score: 3
Z-Score: -42.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -110336.84
ASTM's Operating margin (%) is ranked lower than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ASTM: -110336.84 )
ASTM' s 10-Year Operating margin (%) Range
Min: -161333.33   Max: -656.25
Current: -110336.84

-161333.33
-656.25
Net-margin (%) -82221.05
ASTM's Net-margin (%) is ranked lower than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ASTM: -82221.05 )
ASTM' s 10-Year Net-margin (%) Range
Min: -140352.38   Max: -618.75
Current: -82221.05

-140352.38
-618.75
ROE (%) -401.18
ASTM's ROE (%) is ranked lower than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. ASTM: -401.18 )
ASTM' s 10-Year ROE (%) Range
Min: -401.18   Max: -35.76
Current: -401.18

-401.18
-35.76
ROA (%) -169.53
ASTM's ROA (%) is ranked higher than
50% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ASTM: -169.53 )
ASTM' s 10-Year ROA (%) Range
Min: -254.14   Max: -34.84
Current: -169.53

-254.14
-34.84
ROC (Joel Greenblatt) (%) -2836.81
ASTM's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. ASTM: -2836.81 )
ASTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3340.41   Max: -101.35
Current: -2836.81

-3340.41
-101.35
Revenue Growth (%) -47.70
ASTM's Revenue Growth (%) is ranked higher than
58% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ASTM: -47.70 )
ASTM' s 10-Year Revenue Growth (%) Range
Min: -75.1   Max: 12.5
Current: -47.7

-75.1
12.5
EBITDA Growth (%) -28.90
ASTM's EBITDA Growth (%) is ranked higher than
60% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ASTM: -28.90 )
ASTM' s 10-Year EBITDA Growth (%) Range
Min: -47.6   Max: 6.4
Current: -28.9

-47.6
6.4
EPS Growth (%) -28.80
ASTM's EPS Growth (%) is ranked higher than
63% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ASTM: -28.80 )
ASTM' s 10-Year EPS Growth (%) Range
Min: -49.1   Max: 7.3
Current: -28.8

-49.1
7.3
» ASTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ASTM Guru Trades in Q2 2013

Jim Simons 120,454 sh (New)
» More
Q3 2013

ASTM Guru Trades in Q3 2013

Jim Simons 434,187 sh (-81.98%)
» More
Q4 2013

ASTM Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q1 2014

ASTM Guru Trades in Q1 2014

Jim Simons 64,743 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ASTM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -2.74
ASTM's EV-to-EBIT is ranked higher than
50% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ASTM: -2.74 )
ASTM' s 10-Year EV-to-EBIT Range
Min: 3.2   Max: 21.6
Current: -2.74

3.2
21.6
Current Ratio 1.51
ASTM's Current Ratio is ranked higher than
55% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ASTM: 1.51 )
ASTM' s 10-Year Current Ratio Range
Min: 0.3   Max: 45.43
Current: 1.51

0.3
45.43
Quick Ratio 1.51
ASTM's Quick Ratio is ranked higher than
58% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ASTM: 1.51 )
ASTM' s 10-Year Quick Ratio Range
Min: 0.3   Max: 45.15
Current: 1.51

0.3
45.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.37
ASTM's Price/Net Cash is ranked higher than
86% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. ASTM: 7.37 )
ASTM' s 10-Year Price/Net Cash Range
Min: 1.77   Max: 912
Current: 7.37

1.77
912
Earnings Yield (Greenblatt) 92.40
ASTM's Earnings Yield (Greenblatt) is ranked higher than
89% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. ASTM: 92.40 )
ASTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.6   Max: 1521.1
Current: 92.4

4.6
1521.1
Forward Rate of Return (Yacktman) -366.49
ASTM's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. ASTM: -366.49 )
ASTM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.9   Max: 12.7
Current: -366.49

8.9
12.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ATQP.Germany
Aastrom Biosciences, Inc., was incorporated in 1989 and is a regenerative medicine company focused on the development of innovative cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. Ixmyelocel-T (the generic name for a multicellular therapy) is a disease modifying therapy with multi-functional properties including: tissue remodeling, immuno-modulation and the promotion of angiogenesis. The Company's proprietary cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patient's own bone marrow, to be delivered directly to damage tissues. Preclinical and clinical data suggest that ixmyelocel-T may be safe and effective in treating patients with severe, chronic ischemic cardiovascular diseases such as critical limb ischemia (CLI), the severe form of peripheral arterial disease (PAD), and dilated cardiomyopathy (DCM), the third leading cause of heart failure. Over 200 patients have been treated in recent clinical trials using ixmyelocel-T, and over 400 patients safely treated since the Company's inception. In November2011, the Company released positive Phase 2b data from its RESTORE-CLI clinical trial and launched a pivotal Phase 3 REVIVE trial in CLI in February2012. During the fourth quarter of 2012, it launched a randomized, placebo-controlled, double-blinded Phase 2b ixCELL-DCM trial for patients with ischemic DCM. Ixmyelocel-T is a patient-specific, expanded multicellular therapy developed using the Company's proprietary, fully-closed, automated processing system. Ixmyelocel-T is a product derived from an adult patient's own bone marrow but it is significantly enhanced compared with the original bone marrow. Its process enhances the patient's bone marrow mononuclear cells by expanding the mesenchymal stromal cells and M2 anti-inflammatory macrophages while retaining many of the hematopoietic cells. These cell types, known to regulate the immune response, are important in the resolution of pathologic inflammation and tissue repair. The manufacture of its patient-specific, expanded multicellular therapies is done under current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) guidelines required by the U.S. Food and Drug Administration (FDA). The Company's therapy is produced at its cell manufacturing facility in the United States, located at its headquarters in Ann Arbor, Michigan. Its clinical development programs are focused on addressing areas of high unmet medical needs in severe, chronic ischemic cardiovascular diseases. The Company has exclusive rights to approximately 19 unexpired issued U.S. patents. Eleven of these patents are material patents that protect its cellular therapy. It owns ten of these patents and one has been licensed exclusively from the University of Michigan. T
» More Articles for ASTM

Headlines

Articles On GuruFocus.com
comment on ASTM Jan 10 2013 
Weekly CFO Sells Highlight: P, MTOR, PSSI, ASTM Jan 09 2012 
Weekly CFO Buys Highlight: OCWEN FINANCIAL Corp., Aastrom Biosciences Inc. Mar 13 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Aastrom Biosciences Inc. (ASTM) CEO Timothy M Mayleben buys 17,200 Shares Aug 31 2010 
Aastrom Biosciences Inc. (ASTM) CFO Scott Durbin buys 16,463 Shares Aug 27 2010 

More From Other Websites
Aastrom Announces Appointment of Zac Taylor as National Sales Director Jul 14 2014
Aastrom Announces Appointment of Zac Taylor as National Sales Director Jul 14 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 11 2014
Aastrom Biosciences Added to Russell Microcap Index Jun 30 2014
Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC Jun 24 2014
Time To Buy Aastrom Biosciences Jun 17 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets,... Jun 16 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Other... Jun 16 2014
Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine... Jun 16 2014
Aastrom Announces Investor Conference Call and Webcast June 16, 2014 at 8:30 AM EDT Jun 15 2014
Aastrom appoints Michel CFO Jun 04 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jun 04 2014
Aastrom Announces Appointment of Gerard Michel as Chief Financial Officer and Vice President,... Jun 04 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Jun 02 2014
Aastrom Completes Acquisition of Sanofi's Cell Therapy and Regenerative Medicine Business Jun 02 2014
AASTROM BIOSCIENCES INC Financials May 23 2014
Deal To Acquire Sanofi's CTRM Could Double Shares Of Aastrom Biosciences May 20 2014
Aastrom Biosciences' (ASTM) CEO Dominick Colangelo on Q1 2014 Results - Earnings Call Transcript May 15 2014
AASTROM BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report May 15 2014
Aastrom reports Q1 EPS ($1.26), consenus (92c) May 15 2014
Aastrom Biosciences Reports First-Quarter 2014 Financial Results May 15 2014
Q1 2014 Aastrom Biosciences Earnings Release - After Market Close May 15 2014
AASTROM BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers May 12 2014
Nasdaq stocks posting largest percentage decreases Apr 14 2014
Aastrom Biosciences to Present at the 2014 Regen Med Investor Day Mar 19 2014
Aastrom Biosciences Reports Fourth-Quarter and Year-End 2013 Financial Results Mar 13 2014
Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014 Mar 06 2014
Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia Dec 19 2013
Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement Nov 15 2013
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results Nov 12 2013
Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference Nov 12 2013
Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy Nov 01 2013
Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement Oct 31 2013
Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations,... Aug 12 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide